期刊
AMERICAN JOURNAL OF KIDNEY DISEASES
卷 63, 期 6, 页码 1049-1059出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2013.12.016
关键词
Chronic kidney disease; dialysis; osteoporosis; renal osteodystrophy; fractures; bone mineral density; imaging; biomarkers; histomorphometry
资金
- Baxter
- ONO Pharma
- Fonterra
- Alere
- Janssen
- Johnson Johnson
- Immuno Diagnostic Systems
- Merck
- Amgen
- Warner Chilcott
- AstraZeneca
- Sanofi
- Shire
- MRC [MR/K006312/1] Funding Source: UKRI
- Kidney Research UK [TF2/2014] Funding Source: researchfish
- Medical Research Council [MR/K006312/1] Funding Source: researchfish
Both chronic kidney disease (CKD) and osteoporosis are major public health problems associated with an aging population. Osteoporosis is characterized by reduced bone mineral density, while CKD results in qualitative changes in bone structure; both conditions increase the predisposition to fragility fractures. There is a significant coprevalence of osteoporotic fractures and CKD, particularly in the elderly population. Not only is the risk of fracture higher in the CKD population, but clinical outcomes are significantly worse, with substantial health care costs. Management of osteoporosis in the CKD population is particularly complex given the impact of renal osteodystrophy on bone quality and the limited safety and hard outcome data for current therapy in patients with severe CKD or on dialysis therapy. In this review, we discuss the pathophysiology of osteoporosis, the impact of CKD on bone strength, and the role of novel imaging techniques and biomarkers in predicting underlying renal osteodystrophy on bone histomorphometry in the context of CKD. (C) 2014 by the National Kidney Foundation, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据